ClinicalTrials.gg
CompletedNCT01102660Updated Aug 22, 2014

Clinical Trial to Examine the Pain Relief of PH-797804 Alone Or With Naproxen in Subjects With Osteoarthritis of the Knee

A Phase 2 interventional study of PH-797804 and Placebo in Osteoarthritis, sponsored by Pfizer. Completed at 26 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-08-22.

Primary conditionOsteoarthritis, KneeRegistry: OsteoarthritisReclassifiedWhy we changed it
Registry
Osteoarthritis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Osteoarthritis, Knee
Why
  1. The study's title name Osteoarthritis, Knee, a narrower term within Osteoarthritis.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
172
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 17 studies in Osteoarthritis, Knee by Pfizer — 2 open to participants now, 2 under way, 2 of them phase 3. Osteoarthritis, Knee · Pfizer.

Enrollment
11th of 17
172 · median 200
Started
2010
with 1 other
Phase 2
8 of 17
none open now
Registered
8th of 17
by date

Among the 17 studies in Osteoarthritis, Knee by Pfizer, this one is the 11th largest by enrollment, is one of 2 that started in 2010, is one of 8 in phase 2, and was the 8th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

2 of the 17 studies in Osteoarthritis, Knee by Pfizer are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Osteoarthritis, Knee by Pfizer, or all of them as a file.
02

Study summary

PH-797804 is a potent inhibitor of inflammatory mediators that have a potential role in pain signalling following nerve injury and inflammation. Blocking such mediators may potentially have a therapeutic benefit by reducing pain.

03

Conditions studied

  • Osteoarthritis

Browse trials for

Keywords

  • Knee osteoarthritis
  • clinical trial
  • cross-over
04

In context

Osteoarthritis, Knee Reclassified

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

This study's enrollment of 172 is above the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.

Browse Osteoarthritis, Knee studies →

Lead sponsor

Pfizer is the lead sponsor of 3,338 studies on the registry; 147 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 393 (65%) have results posted.

Compared within Osteoarthritis, Knee, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Osteoarthritis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects between, and including, the ages of 18 and 75 years. Females must be of non-.
  • Diagnosis of osteoarthritis of the knee based on American College of Rheumatology criteria with X-ray confirmation (a Kellgren-Lawrence X-ray grade of ≥2.

Exclusion criteria

Exclusion Criteria:

  • History of diseases other than osteoarthritis that may involve the index knee.
  • Other severe pain that impairs the assessment of osteoarthritis of pain.
  • abnormalities.
  • History of gastrointestinal disorders.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
172 participants (actual)

Study arms

  • Other
    Treatment Sequence 1

    Drug: PH-797804 · Drug: Placebo

  • Other
    Treatment Sequence 2

    Drug: Placebo · Drug: PH-797804

  • Other
    Treatment Sequence 3

    Drug: Naproxen · Drug: Naproxen + PH-797804

  • Other
    Treatment Sequence 4

    Drug: Naproxen + PH-797804 · Drug: Naproxen

Interventions

07

What researchers measure

Primary outcomes

  1. Western Ontario & McMaster Osteoarthritis Index Pain Score

    Time frame: 2 weeks

Secondary outcomes

  1. Western Ontario & McMaster Osteoarthritis Index Stiffness Score

    Time frame: 2 weeks

  2. Western Ontario & McMaster Osteoarthritis Index Physical Function Score

    Time frame: 2 weeks

  3. Western Ontario & McMaster Osteoarthritis Index Total Score

    Time frame: 2 weeks

  4. Daily Pain Rating Scale

    Time frame: 2 weeks

08

Study locations

26 sites
  • Pfizer Investigational Site
    Paramount, California 90723, United States
  • Pfizer Investigational Site
    Spring Valley, California 91978, United States
  • Pfizer Investigational Site
    Valley Village, California 91607, United States
  • Pfizer Investigational Site
    Daytona Beach, Florida 32117, United States
  • Pfizer Investigational Site
    Ormond Beach, Florida 32174, United States
  • Pfizer Investigational Site
    Plantation, Florida 33317, United States
  • Pfizer Investigational Site
    Plantation, Florida 33324, United States
  • Pfizer Investigational Site
    South Miami, Florida 33143, United States
  • Pfizer Investigational Site
    Gurnee, Illinois 60031, United States
  • Pfizer Investigational Site
    Overland Park, Kansas 66211, United States
  • Pfizer Investigational Site
    Overland Park, Kansas 66212, United States
  • Pfizer Investigational Site
    Overland Park, Kansas 66215, United States
  • Pfizer Investigational Site
    Prairie Village, Kansas 66206, United States
  • Pfizer Investigational Site
    Wichita, Kansas 67206, United States
  • Pfizer Investigational Site
    Fall River, Massachusetts 02721, United States
  • Pfizer Investigational Site
    Hyannis, Massachusetts 02601, United States
  • Pfizer Investigational Site
    New Bedford, Massachusetts 02740, United States
  • Pfizer Investigational Site
    St. Louis, Missouri 63141, United States
  • Pfizer Investigational Site
    Rochester, New York 14609, United States
  • Pfizer Investigational Site
    Wilmington, North Carolina 28401, United States
  • Pfizer Investigational Site
    Kettering, Ohio 45429, United States
  • Pfizer Investigational Site
    Pawtucket, Rhode Island 02860, United States
  • Pfizer Investigational Site
    Mt. Pleasant, South Carolina 29464, United States
  • Pfizer Investigational Site
    New Tazewell, Tennessee 37825, United States
  • Pfizer Investigational Site
    Dallas, Texas 75235, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78209, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010, a primary completion of Feb 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2010
First posted
Apr 13, 2010
Start
May 2010
Primary completionActual
Feb 2011
CompletionActual
Mar 2011
Results delay requested
Oct 1, 2012
Last update
Aug 22, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01102660
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 13, 2010
Start date
May 2010
Primary completion
Feb 2011
Completion
Mar 2011
Last update
Aug 22, 2014

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: PH 797804 · Naproxen

Start the discussion